Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status
Hematological Oncology (2015)
  • Maika Onishi, University of Washington
  • Solomon A. Graf, Fred Hutchinson Cancer Research Center
  • Leona Holmberg, Fred Hutchinson Cancer Research Center
  • Sanaz Behnia, University of Washington
  • Andrei R. Shustov, Fred Hutchinson Cancer Research Center
  • Karen Schiavo, Fred Hutchinson Cancer Research Center
  • Mary Philip, Fred Hutchinson Cancer Research Center
  • Edward N. Libby, Fred Hutchinson Cancer Research Center
  • Ryan D. Cassaday, Fred Hutchinson Cancer Research Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jennifer E. Roden, Fred Hutchinson Cancer Research Center
  • David G. Maloney, Fred Hutchinson Cancer Research Center
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • Brian G. Till, Fred Hutchinson Cancer Research Center
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
  • Stephen D. Smith, Fred Hutchinson Cancer Research Center
  • Ajay K. Gopal, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
January 12, 2015
DOI
10.1002/hon.2166
Citation Information
Maika Onishi, Solomon A. Graf, Leona Holmberg, Sanaz Behnia, et al.. "Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status" Hematological Oncology Vol. 33 Iss. 4 (2015) p. 187 - 191
Available at: http://works.bepress.com/john-pagel/74/